Isotope-labeled Protease & Enzyme Inhibitors for Bioanalysis

What Are Protease and Enzyme Inhibitors?

Protease and enzyme inhibitors are molecules that reduce or block the catalytic activity of enzymes. Proteases are a large class of enzymes that cleave peptide bonds in proteins; inhibiting proteases (e.g., viral proteases, digestive proteases, or proteases involved in blood coagulation) is a proven therapeutic strategy. More generally, "enzyme inhibitors" target any catalytic protein (kinases, phosphodiesterases, reductases, etc.) to modulate biochemical pathways for therapeutic benefit or as research tools.

Isotope-labeled protease and enzyme inhibitors are a mainstay of modern drug discovery, preclinical pharmacokinetics (PK), clinical bioanalysis, and mechanistic enzymology. Isotope labels (¹³C, ¹⁵N, D/deuterium) provide a chemically identical, but mass-shifted analog that can be used by analytical labs to improve quantitation, robustness, and clarity of data interpretation.

Why Use Isotope-Labeled Inhibitors?

• Accurate quantitation: Labeled internal standards are co-eluting with the analyte, and help correct for extraction/ionization/matrix effects in LC-MS/MS workflows.
• Metabolic tracing / mechanistic studies: Stable isotopes enable tracking of drug biotransformation pathways, identification of metabolites, and study of enzymatic mechanisms without radioactive hazards.
• Improved method validation: Using isotopically labeled standards helps meet regulatory expectations for precision, accuracy, and reproducibility.
• Assay robustness: Labels placed at metabolically stable positions reduce risks of back-exchange or isotope scrambling, preserving quantitative integrity.

Alfa Chemistry's Portfolio of Isotope-Labeled Enzyme Inhibitors

Alfa Chemistry's custom isotope lab offers a large catalog of high-purity stable isotope-labeled compounds, including inhibitors targeted to key therapeutic areas and enzymes classes. The following table highlights some of the products currently in our catalog, grouped by their primary target or research area:

Guidance for Selecting the Right Labeled Inhibitor

Choosing the appropriate isotope-labeled compound is vital for experimental success. Consider these key factors:

1. Label Position (Site-Specific vs. Uniform): If your primary goal is to use the inhibitor as a quantitative internal standard, or to track metabolic "soft spots" (single unlabeled atoms that are preferentially lost during metabolism), then site-specific deuterium labeling at a non-labile position (or ¹⁵N labeling if available) will be most appropriate. If you are primarily using the compound for NMR-based structural studies, proteomics, or detailed mechanistic investigations, then a uniformly labeled isotope (e.g., U-¹³C₆) may be a better choice.

2. Isotopic Purity and Chemical Purity: High isotopic purity (often >98% or >99%) ensures that the MS signal from the label is strong and unambiguous. Similarly, high chemical purity is necessary to avoid interference from impurities in sensitive biological assays.

3. Application-First Selection: Clearly define your primary goal.

• If you are setting up a quantitative LC-MS/MS bioanalysis method, then you will need a deuterated internal standard with at least 3-4 mass units mass shift (e.g., Finasteride-d9).
• If you are performing NMR spectroscopy, then you will need a ¹³C- or ¹⁵N-labeled compound to provide the necessary nuclear spin for detection.
• If you are doing in vivo metabolite profiling and tracing drug metabolism, then a ¹³C-labeled compound may be more advantageous than a deuterated compound because ¹³C does not undergo exchange while deuterium may under some metabolic conditions.

Applications in Research and Development

The applications of isotope labeled inhibitors are used throughout the drug discovery and development process where they can provide essential information that cannot be obtained by other means.

Drug Metabolism and Pharmacokinetics (DMPK)

Isotope labeled drugs are used for mass balance studies as well as identification of metabolic pathways. Administration of a labeled inhibitor such as Ritonavir-13C,d3 can be used to follow the parent drug and all its metabolites with absolute specificity in complex biological matrices such as plasma, urine or bile. This enables an accurate determination of ADME properties which help to predict drug safety and efficacy.

• Mechanistic and Biomolecular studies

The use of a label allows for studies of the interaction of an enzyme with an inhibitor. The isotope can be used for Stable Isotope Labeling by Amino acids in Cell culture (SILAC) to determine quantitative changes in protein expression and protein-protein interactions due to inhibition. In addition, as shown in the orotidine monophosphate decarboxylase (ODCase) study, synthesis of a substrate double labeled with ¹³C and ¹⁸O allowed isotope effect calculations and experimental determination whether or not a proposed mechanism was correct.

• Quantitative Bioanalysis and Internal Standards

In quantitative MS (LC-MS/MS), a deuterated analog of the analyte such as Boceprevir-d9 or Saquinavir-d9, called an internal standard, is used which undergoes extraction and ionization with nearly identical efficiency as the unlabeled drug but can be distinguished by MS. This practice greatly enhances the precision, accuracy and reproducibility of concentration measurements which is of critical importance for reliable preclinical and clinical assays.

Online Inquiry



mg g kg ml L

Isotope-labeled Protease & Enzyme Inhibitors for Bioanalysis

SUBMIT